A Phase 3 interventional study of dacarbazine and CP-675,206 in Melanoma, sponsored by AstraZeneca. Completed at 144 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-02.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tremelimumab in Melanoma — none open to participants now, none under way, none of them phase 3. tremelimumab · Melanoma.
Among the 12 studies testing tremelimumab in Melanoma, this one has the largest enrollment, is one of 3 that started in 2006, is the only one in phase 3, and was the 3rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 12 studies testing tremelimumab in Melanoma is open now. The open studies under Melanoma, anywhere →
tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tremelimumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 1
First in 2003; this study’s year is marked. 3 started in 2006.
This study's enrollment of 655 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 51 across the 12 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 6 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Melanoma by AstraZeneca: 2 open now, 3 under way, none of them phase 3. Of 17 finished, 2 (12%) have results posted.
Among the 20 studies in Melanoma by AstraZeneca, this one has the largest enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2006, is the only one in phase 3, and was the 5th registered.
AstraZeneca’s Melanoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing tremelimumab in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)
Drug: dacarbazine · Drug: temozolomide
Drug: CP-675,206
decarbazine 1000 mg/m2 IV Q 21 days x 12
CP-675,206 15 mg/kg IV Q 90 days x 4
Also known as: anti-CTLA4 human monoclonal antibody
temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
overall survival
Time frame: August 2010
adverse events
Time frame: 1 year
PFS at 6 months
Time frame: 6 months
objective tumor response
Time frame: 1 year
Durable response
Time frame: 6 months
pharmacokinetics endpoints
Time frame: 15 months
pharmacogenomic endpoints
Time frame: 1 year
HQol
Time frame: 1 year
healthcare resource utilization and loss of productivity
Time frame: 1 year
human antihuman antibody response for patients in Arm A
Time frame: 15 months
Showing the first 100 of 144 sites across 21 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2006, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab